Targets › B3GNT1
1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2029.
Beta-1,4-glucuronyltransferase involved in O-mannosylation of alpha-dystroglycan (DAG1). Transfers a glucuronic acid (GlcA) residue onto a xylose (Xyl) acceptor to produce the glucuronyl-beta-1,4-xylose-beta disaccharide primer, which is further elongated by LARGE1, during synthesis of phosphorylated O-mannosyl glycan. (UniProt, O43505)
Open in Phaseline: the race on B3GNT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Robbie Majzner | B7-H3.CD28Z.CART CAR-T cell therapy targeting B7-H3 with CD28 costimulatory domain | B3GNT1 | Phase 1 | Pediatric Solid Tumor; Central Nervous System Neoplasms | Dec 2029 |
Pediatric Solid Tumor (1) Central Nervous System Neoplasms (1)
mixed (1)
Robbie Majzner (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.